Garima Singh

Garima Singh

Auto-generated profile, based on publicly available information

Garima Singh

Cell Cycle and Cancer Laboratory, School of Biotechnology, Institute of Science, Banaras Hindu University, Varanasi, India

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2023 in Discover Oncology
Verified
Journal Article
Open access
PDF file
GSGarima Singh
Garima Singh
SSSonika Kumari Sharma
Sonika Kumari Sharma
ADAastha Dorata
Aastha Dorata
SSSamarendra Kumar Singh
Samarendra Kumar Singh
Cervical cancer (CC) is the 4th most leading cause of death among women worldwide, and if diagnosed in late stages the treatment options are almost negligible. 99% of CC is caused by high-risk human papilloma viruses (HR-HPV). Upon integration into human genome, the encoded viral proteins mis-regulate various onco-suppressors and checkpoint factors including cell cycle regulators. One such protein is cell cycle S phase licensing factor, CDC-10 dependent transcript-2 (Cdt2) which has been reported to be highly upregulated in various cancers including CC. Also, in CC cells, several tumor suppressor miRNAs are suppressed, including miR-17 ~ 92 cluster. In this study, we report that miR-17 ~ 92 directly recruits to 3’UTR of Cdt2 and downregulates this oncogene which suppresses the proliferation, migration and invasion capabilities of the CC cell lines without affecting non-cancerous cells. We further show that suppression of Cdt2 by miR-17 ~ 92, blocks the cancerous cells in S phase and induces apoptosis, eventually leading to their death. Hence, our work for the first time, mechanistically shows how miR-17 ~ 92 could work as tumor suppressor in cervical cancer cells, opening up the potential of miR-17 ~ 92 to be used in developing therapy for cervical cancer treatment.

20 July 2017 in International Journal of Radiology & Radiation Therapy
Verified
Journal Article
Open access
PDF file
GSGarima Singh
Garima Singh
DSDeepti Sharma
Deepti Sharma

1 January 2015 in Journal of Clinical and Diagnostic Research
Verified
Journal Article
Open access
VMVandana Markam
Vandana Markam
NBNaveen Reddy Banda
Naveen Reddy Banda
GSGarima Singh
Garima Singh
KPKalyana Chakravarthy Pentapati
Kalyana Chakravarthy Pentapati
Manoj GuptaManoj Gupta
Manoj Gupta
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.

28 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
GSGarima Singh
Garima Singh
SSSonika Kumari Sharma
Sonika Kumari Sharma
SSSamarendra Kumar Singh
Samarendra Kumar Singh
MicroRNAs have emerged as an important factor in regulating cell cycle and various other cellular processes. Aberration in microRNAs has been linked with development of several cancers and other diseases but still very little is known about the mechanism behind their function in regulating cellular processes. 99% of cervical cancer is caused by the infection of high-risk HPVs (HR HPVs) which suppresses multiple tumor suppressors and checkpoint factors of the host cell. It also stabilizes oncogenic proteins, one of them is Cdt2/DTL which promotes cell transformation and proliferation. In this study, we have reported that in cervical cancer cell lines miR-34a by targeting HPV E6 protein, regulates Cdt2/DTL protein level and leads to its destabilization. Destabilization of Cdt2 stabilizes onco-suppressor proteins like p21 and Set8 in these cell lines. We have also shown that the overexpression of miR-34a suppresses cell proliferation, invasion and migration capabilities of HPV positive cervical cancer cells which was reverted by overexpression of either HPV E6 or Cdt2 genes. This is the first-ever report to show that miR-34a regulates cell cycle factor Cdt2 by suppressing viral E6 protein level, which opens up the scope of exploring miR-34a as a specific therapy for cervical cancer treatment. Abstract Figure:

29 July 2023 in Bengal Journal of Otolaryngology and Head Neck Surgery
Verified
Journal Article
Open access
PDF file
RCRavishankar C
Ravishankar C
HRHemalatha B R
Hemalatha B R
PSPruthvi Raj S
Pruthvi Raj S
APArchitha Menon P
Architha Menon P
GSGarima Singh
Garima Singh
Introduction:Mandibular involvement in mucormycosis is rare, and only a few cases of post covid-19 mandibular mucormycosis have been reported to date. Materials & methods: This is a retrospective descriptive case series study conducted at a tertiary care centre.We report the clinico-epidemiological profile and management of 5 cases of post covid mandibular mucormycosis. All patients received intravenous antifungals at the earliest and underwent surgical debridement of the infected bone. Results: 4 patients were managed satisfactorily. 1 patient succumbed to the disease. Extent of debridement was based on the clinical, radiological and intraoperative assessment of the mandible. Conclusion: Mandibular mucormycosis is rare and early recognition of symptoms and treatment is imperative in reducing the spread of disease, decreasing the extent of resection and postoperative reconstruction.